Crossmark

High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group

Crossref DOI link: https://doi.org/10.1186/s13045-015-0215-4

Published Online: 2015-10-20

Published Print: 2015-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Laszlo, George S.

Alonzo, Todd A.

Gudgeon, Chelsea J.

Harrington, Kimberly H.

Kentsis, Alex

Gerbing, Robert B.

Wang, Yi-Cheng

Ries, Rhonda E.

Raimondi, Susana C.

Hirsch, Betsy A.

Gamis, Alan S.

Meshinchi, Soheil

Walter, Roland B.
Funding

Funding for this research was provided by:

National Cancer Institute (R21-CA161894, U10-CA098543, U10-CA180899, U24-CA114766)

Leukemia and Lymphoma Society (2311-15)
License Information

Text and Data Mining valid from 2015-10-20

Version of Record valid from 2015-10-20
More Information

Article History

Received: 24 August 2015

Accepted: 13 October 2015

First Online: 20 October 2015

Updates are available Correction dated 2016-11-30

Click to view Correction: https://doi.org/10.1186/s13045-016-0364-0